Efficacy, Safety and Tolerability Study of Glatiramer Acetate in Subjects With Multiple Sclerosis

- Relapsing-Remitting Multiple Sclerosis
- Terminated

Study Title: An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Teva Identifier: GA-MS-302 | 2011-005550-57

ClinicalTrials.gov Identifier: NCT01578785

Study Status: Terminated

Trial Condition(s): Relapsing-Remitting Multiple Sclerosis

Interventions: Drug: Glatiramer Acetate | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age group: Adult

Age Range: 18 Years to 55 Years

Trial Duration: 03/01/2012 - 11/01/2012

Phase: Phase 3

Study Type

Interventional